TLR9 and neoplasm: Targeting of TLR9 agonist to the tumor tissue is thought to enable the priming of antigen-specific T cells in the draining lymph nodes, to promote the tumor infiltration with effector cells and to disable immune checkpoints in the tumor tissue leading to efficient anti-tumor responses [45].